Polly A. Murphy is Director at Atea Pharmaceuticals, Inc. (AVIR). They have made 4 open-market trades across 2 companies since 2021, most recently 2026-06-18.
CIK 0001829248
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
4 open-market purchases totalling $202K since 2021, never a sale. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| AVIR | 121,745 | $527K |
| CELC | 6,530 | $369K |
| Total | $897K |
Shares reported on the most recent Form 4, priced at the 2026-06-23 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.